Health Care • Misc Health and Biotechnology Services
$0.25 ▼ +0.00
(-1.47%)
MKT CAP: $5.7M • VOL: 234.0K
52W L $0 52W H $2
MGRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $456.0K | $615.9K | $731.5K |
| YoY Revenue Growth % | -26.0% | -15.8% | — |
| Gross Profit | $250.4K | $380.0K | — |
| Gross Margin % | 54.9% | 61.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.0M | -$8.0M | -$9.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$20.6M | -$8.7M | -$9.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.9M | -$4.9M | -$7.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.9M | -$4.9M | -$7.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.5M | $58.7K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $15.2M | $13.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MGRX.